MilliporeSigma
  • MPC1 deficiency accelerates lung adenocarcinoma progression through the STAT3 pathway.

MPC1 deficiency accelerates lung adenocarcinoma progression through the STAT3 pathway.

Cell death & disease (2019-02-17)
Hongbo Zou, Qian Chen, Anmei Zhang, Songtao Wang, Hong Wu, Ye Yuan, Shuang Wang, Jing Yu, Mao Luo, Xianmei Wen, Wei Cui, Wenjuan Fu, Ruilian Yu, Lin Chen, Ming Zhang, Haitao Lan, Xia Zhang, Qichao Xie, Guoxiang Jin, Chuan Xu
ABSTRACT

Mitochondrial pyruvate carrier 1 (MPC1), a key factor that controls pyruvate transportation in the mitochondria, is known to be frequently dysregulated in tumor initiation and progression. However, the clinical relevance and potential molecular mechanisms of MPC1 in lung adenocarcinoma (LAC) progression remain to be illustrated. Herein, MPC1 was lowly expressed in LAC tissues and significantly associated with favorable survival of patients with LAC. Functionally, MPC1 markedly suppressed stemness, invasion, and migration in vitro and spreading growth of LAC cells in vivo. Further study revealed that MPC1 could interact with mitochondrial signal transducer and activator of transcription 3 (mito-STAT3), disrupting the distribution of STAT3 and reducing cytoplasmic signal transducer and activator of transcription 3 (cyto-STAT3) as well as its phosphorylation, while the activation of cyto-STAT3 by IL-6 reversed the attenuated malignant progression in MPC1-overexpression LAC cells. Collectively, we reveal that MPC1/STAT3 axis plays an important role in the progression of LAC, and our work may promote the development of new therapeutic strategies for LAC.